Kosuke Tanaka
17 Papers
2 Citations
Kosuke Tanaka is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 2, co-authored 9 publications.
Chat about Author
Papers
Tumor‑infiltrating CD8+ T cells as a biomarker for chemotherapy efficacy in unresectable hepatocellular carcinoma
A. Kuwano,Masayoshi Yada,Kosuke Tanaka,Kazuki Kurosaka,Yoshihiro Ohishi,Akihide Masumoto,Kenta Motomura +6 more
TL;DR: In this paper , the authors investigated whether evaluating CD8+ tumor-infiltrating lymphocytes (TILs) by immunohistochemistry staining of liver tumor biopsy tissues could help predict the response of patients with advanced hepatocellular carcinoma (HCC) to atezolizumab plus bevacsumab and lenvatinib.
12
Hepatitis C virus eradication ameliorates the prognosis of advanced hepatocellular carcinoma treated with sorafenib
A. Kuwano,Masayoshi Yada,Shigehiro Nagasawa,Kosuke Tanaka,Yusuke Morita,Akihide Masumoto,Kenta Motomura +6 more
TL;DR: HCV eradication may serve an important role in the survival outcome of advanced HCC patients treated with sorafenib and was significantly longer in the HCV eradications group than in theHCV non‐eradication group.
8
Potential Predictive Biomarkers of Systemic Drug Therapy for Hepatocellular Carcinoma: Anticipated Usefulness in Clinical Practice.
Kenta Motomura,A. Kuwano,Kosuke Tanaka,Yuta Koga,Akihide Masumoto,Masayoshi Yada +5 more
TL;DR: An overview of extensive research conducted on potential HCC biomarkers from blood, tissue, or imaging information that can be used in practice to predict the therapeutic efficacy of systemic therapy before its initiation is provided.
5
An Imaging Feature Predicts Efficacy of Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
TL;DR: In this article , the efficacy of atezolizumab plus bevacizumaab for hepatocellular carcinoma (HCC) using computed tomography (CT) or magnetic resonance imaging (MRI) imaging features was investigated.
Risk factors for loss to follow‐up after the start of direct‐acting antiviral treatment for hepatitis C virus infection
TL;DR: In this paper , the authors identified the definitive risk factors for loss to follow-up after the start of DAA treatment and showed that interferon-free Daa treatment has improved liver function and reduced the risk of hepatocellular carcinoma (HCC) following HCV eradication.
3